Colin R James
Overview
Explore the profile of Colin R James including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
458
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Parkes E, Savage K, Lioe T, Boyd C, Halliday S, Walker S, et al.
Br J Cancer
. 2021 Nov;
126(2):247-258.
PMID: 34728791
Background: The DNA-damage immune-response (DDIR) signature is an immune-driven gene expression signature retrospectively validated as predicting response to anthracycline-based therapy. This feasibility study prospectively evaluates the use of this assay...
2.
Mulligan J, Hill L, Deharo S, Irwin G, Boyle D, Keating K, et al.
J Natl Cancer Inst
. 2014 Jan;
106(1):djt335.
PMID: 24402422
Background: There is no method routinely used to predict response to anthracycline and cyclophosphamide-based chemotherapy in the clinic; therefore patients often receive treatment for breast cancer with no benefit. Loss...
3.
Krell J, James C, Shah D, Gojis O, Lim A, Riddle P, et al.
Clin Breast Cancer
. 2011 Jun;
11(3):153-60.
PMID: 21665135
Background: The purpose of this study is to evaluate the response to and benefit of first-line metastatic treatment (including re-exposure to trastuzumab) for patients relapsing after exposure to adjuvant trastuzumab...
4.
Palmieri C, Krell J, James C, Harper-Wynne C, Misra V, Cleator S, et al.
Nat Rev Clin Oncol
. 2010 Sep;
7(10):561-74.
PMID: 20808300
Adjuvant use of anthracycline-taxane combination therapy is an accepted strategy in the management of high-risk early-stage breast cancer. However, the introduction of this regimen raises the question of how best...
5.
Gorski J, James C, Quinn J, Stewart G, Staunton K, Buckley N, et al.
Breast Cancer Res Treat
. 2009 Nov;
122(3):721-31.
PMID: 19882246
Expression profiling of BRCA1-deficient tumours has identified a pattern of gene expression similar to basal-like breast tumours. In this study, we examine whether a BRCA1-dependent transcriptional mechanism may underpin the...
6.
Quinn J, Carser J, James C, Kennedy R, Harkin D
Gynecol Oncol
. 2009 Jan;
113(1):134-42.
PMID: 19168207
Objectives: Treatment of epithelial ovarian cancer (EOC) remains a challenge, despite advances in surgery and chemotherapy. Hereditary ovarian cancer is primarily due to germline mutations in the BRCA1 tumour suppressor...
7.
Quinn J, James C, Stewart G, Mulligan J, White P, Chang G, et al.
Clin Cancer Res
. 2007 Dec;
13(24):7413-20.
PMID: 18094425
Purpose: We investigated whether BRCA1 mRNA expression levels may represent a biomarker of survival in sporadic epithelial ovarian cancer following chemotherapy treatment. Experimental Design: The effect of loss of BRCA1...
8.
Hosey A, Gorski J, Murray M, Quinn J, Chung W, Stewart G, et al.
J Natl Cancer Inst
. 2007 Nov;
99(22):1683-94.
PMID: 18000219
Background: BRCA1-mutant breast tumors are typically estrogen receptor alpha (ER alpha) negative, whereas most sporadic tumors express wild-type BRCA1 and are ER alpha positive. We examined a possible mechanism for...
9.
James C, Quinn J, Mullan P, Johnston P, Harkin D
Oncologist
. 2007 Feb;
12(2):142-50.
PMID: 17296808
To date, estrogen receptor, progestogen receptor, and HER2/neu represent molecular biomarkers currently used in routine clinical practice to aid treatment decisions. Over the last few years, a large body of...
10.
Kennedy R, Gorski J, Quinn J, Stewart G, James C, Moore S, et al.
Cancer Res
. 2005 Nov;
65(22):10265-72.
PMID: 16288014
Evidence is accumulating to suggest that some of the diverse functions associated with BRCA1 may relate to its ability to transcriptionally regulate key downstream target genes. Here, we identify S100A7...